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Background: In women signs and symptoms of ischemia with no obstructive coronary artery disease (CAD), persistent angina (defined as 
continuing chest pain at 1 year after angiography) predicts adverse outcomes. However, persistent angina and angina-related quality of life (QoL) in 
this population using a validated tool (Seattle Angina Questionnaire, SAQ) associated with anti-anginal therapy has not been evaluated.
methods: 229 women with signs and symptoms of ischemia but no obstructive CAD in WISE (2009-2012) had baseline and follow-up evaluation, 
including symptom history, QoL, and SAQ.
results: Mean age was 54 ± 11, BMI 31 ± 9 kg/m2, 35% had hypertension, 14% dyslipidemia, 11% diabetes, and 7% were current smokers. 94% 
had angina at baseline; 7% perceived that their health was excellent. Baseline and follow-up SAQ demonstrated mild to moderate angina and a 
compromised angina-related QoL (Table). At 1 year follow-up, usual care anti-anginal medication use was unchanged except for ranolazine which 
increased from 6% to 17% (p=0.0006).  Although SAQ scores improved significantly (Table), 74% continued to have angina.
conclusions: Persistent angina is highly prevalent in women with signs and symptoms of ischemia but no obstructive CAD. Usual care anti-anginal 
therapy may be associated with improved SAQ, although a majority continued to have angina. Randomized clinical trials aimed at testing therapeutic 
strategies are needed to advise guidelines for management in this population. 
SAQ subscales
Range: (0 - 100);
0 = worst, 100 = best
At Baseline
(n = 229)
At 1-year Follow-up
(n = 147)
p-value
Physical Limitation 69 ± 24 71 ± 24 0.73
Angina Stability 49 ± 26 54 ± 22 0.14
Angina Frequency 64 ± 27 74± 24 <0.0001
Treatment Satisfaction 72 ± 25 80 ± 19 0.03
Quality of Life 52 ± 25 67± 22 <0.001
